Visit the News Hub Targeted therapy shrank tumors, shows promise in improving survival Huy Mach The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

Chemotherapy has been the backbone of cancer treatment for decades, but it is notorious for its toxicity to healthy cells, severe side effects, and poor targeting of the intended tumors. Efforts to improve chemotherapy's efficacy and tolerability include packaging drugs into nanoparticles, which can protect them from degradation in the body, control their release pattern, and shield the patient from some of the drugs' side effects.